Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.60 |
| ▸ | PKM | P14618 | 2/20 | 0.54 |
| ▸ | CA12 | O43570 | 6/20 | 0.51 |
| ▸ | CA1 | P00915 | 6/20 | 0.51 |
| ▸ | CA2 | P00918 | 6/20 | 0.51 |
| ▸ | CA4 | P22748 | 2/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.49 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.49 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.49 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.49 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.49 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.49 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3928463 | 0.94 | GRIN2D (0.55) | CNR2PKMLMNAHDAC1HDAC6 | |
| Decane SCHEMBL9298496 | 0.92 | LMNA (0.54) | CNR2PKMCA12CA1CA2 | |
| Hexadecane SCHEMBL9298501 | 0.92 | LMNA (0.54) | CNR2PKMCA12CA1CA2 | |
| SCHEMBL8773510 | 0.89 | CNR2 (0.64) | CNR2PKMCA12CA1CA2 | |
| SCHEMBL15546987 | 0.89 | CNR2 (0.64) | CNR2PKMCA12CA1CA2 | |
| Diphenylmethane SCHEMBL3984520 | 0.88 | KCNH2 (0.50) | CNR2PKMKCNH2 | |
| Diphenylmethane SCHEMBL5889095 | 0.88 | KCNH2 (0.50) | CNR2PKMKCNH2 | |
| SCHEMBL3920435 | 0.87 | LMNA (0.56) | PKMLMNAHDAC1HDAC6GRIN2D | |
| SCHEMBL7271380 | 0.86 | ESR1 (0.53) | CNR2CA12CA1CA2LMNA | |
| SCHEMBL7271448 | 0.86 | ESR1 (0.53) | CNR2CA12CA1CA2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227414-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2023-07-20 | — | — | US | disclosed |
| US-20200157055-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2020-05-21 | — | — | US | disclosed |
| US-20150315157-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2015-11-05 | — | — | US | disclosed |
| US-20140336383-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-11-13 | — | — | US | disclosed |
| US-8815884-B2 | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2014-08-26 | — | — | US | disclosed |
| US-20140024666-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-01-23 | — | — | US | disclosed |
| US-8557834-B2 | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-10-15 | — | — | US | disclosed |
| US-20130072487-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-03-21 | — | — | US | disclosed |
| US-8324208-B2 | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100113444-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024666-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN3, EGLN2 | CNR2 2345/4885PKM 1417/4885CA12 4408/4885 |
| US-20130072487-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN3, EGLN2 | CNR2 2345/4885PKM 1417/4885CA12 4408/4885 |
| US-20100113444-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN3, EGLN2 | CNR2 2657/4885PKM 1324/4885CA12 4403/4885 |
| US-20140336383-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN3, EGLN2 | CNR2 2345/4885PKM 1417/4885CA12 4408/4885 |
| US-20200157055-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | CNR2 2345/4885PKM 1417/4885CA12 4408/4885 |
| US-20230227414-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | CNR2 2345/4885PKM 1417/4885CA12 4408/4885 |
| US-20150315157-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN3, EGLN2 | CNR2 2345/4885PKM 1417/4885CA12 4408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.